CHAPEL HILL, N.C., March 30, 2011 /PRNewswire/ -- Cempra Pharmaceuticals Inc. today announced presentations at two upcoming investor conferences. Prabhavathi Fernandes, Ph.D., president and chief executive officer, will present at the Needham & Company 10th Annual Healthcare Conference at 10 a.m. EDT, April 6, at The New York Palace Hotel in New York City. Mark Hahn, chief financial officer of Cempra, will also be in attendance. Dr. Fernandes will also present at the BioCentury Future Leaders in the Biotech Industry at 3 p.m. EDT, April 15 at the Millennium Broadway Hotel & Conference Center in New York City. Dr. Fernandes will provide an overview of the company’s two leading antibiotic clinical programs, solithromycin for community-acquired bacterial pneumonia and TAKSTATM for the oral treatment of gram positive pathogens including methicillin-resistant S. aureus (MRSA).
About Cempra Pharmaceuticals
Founded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage biotechnology company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially viable products through consideration of pricing and reimbursement issues throughout its products’ lifecycles. The company is also utilizing its proprietary chemistry technology to develop macrolides without antibacterial activity for non-antibiotic uses in motilin receptor activity, anti-inflammatory activity and GnRH receptor antagonism. Additional information about Cempra can be found at www.cempra.com.
Media Contacts:
Robert E. Flamm, Ph.D.
Russo Partners, LLC
(212) 845-4226
Robert.flamm@russopartnersllc.com
Tony Russo, Ph.D.
Russo Partners, LLC
(212) 845-4251
Tony.russo@russopartnersllc.com
SOURCE Cempra Pharmaceuticals
